Research Projects & Grants

College/University

  • All of Us Southern California Consortium, Role: Co-Investigator, University of California, Irvine, (05/2024 - 04/2025) Status: Closed

Federal

  • SWOG - PACCT-1: Program of the assessment of clinical tests (PACCT-1): Trial assigning individualized options for treatment: the TAILORx trial, Role: Investigator, Eastern Cooperative Oncology Group, (11/2024 - 11/2025) Status: Approved
  • NASBP B-27.1 A trial to evaluate the worth of serum ErbB-2 extracellular domain and serum ErbB-2 antibodies in predicting response to preoperative chemotherapy and long-term outcome in patients with operable breast cancer who are participating in NSABP Protocol B-27, Role: Investigator, National Cancer Institute/NIH/DHHS, (07/2009 - 07/2010) Status: Completed
  • NSABP C-06. A clinical trial comparing oral Uracil/Ftorafur plus leucovorin with 5-fluorouraceil (5-FU) plus leucovorin in the treatment of patients stages II and III carcinoma of the colon, Role: Investigator, National Cancer Institute/NIH/DHHS, (08/2008 - 08/2009) Status: Completed
  • NSABP B-21. A clinical trial to determine the worth of tamoxifen and the worth of breast radiation in the management of patients with node-negative, occult, invasive breast cancer treated by lumpectomy, Role: PI, National Cancer Institute/NIH/DHHS, (08/2006 - 08/2007) Status: Completed

For Profit Organization

  • SWOG-A011106:ALTernate approaches for clinical stage II or III estrogen receptor positive breast cancer NeoAdjuvant TreEatment (ALTERNATE) in postmenopausal women: a phase III study, Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
  • SWOG A011202: a randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy, Role: PI, Southwest Oncology Group, (08/2024 - 08/2025) Status: Approved
  • SWOG S1316: Prospective comparative effectiveness trial for malignant bowel obstruction, Role: Investigator, Southwest Oncology Group, (11/2024 - 11/2025) Status: Approved
  • Southwest Oncology Group (SWOG) - S0800: A randomized phase II trial of weekly nanoparticle albumin bound pacilitaxel (nab-pacilitaxel) (NSC-736631) with or without bevacizumab, either preceded by or followed by Q 2 week doxorubicin (A) and cyclophosphamide (c) plus pegfilgrastim (PEG-G) as neoadjuvant therapy for inflammatory and locally advanced her-2/neu negative breast cancer, Role: Investigator, Southwest Oncology Group, (05/2018 - 05/2019) Status: Completed
  • Genentech - U2963n: The national lymphocare study: an observational study of treatment, outcomes, and prognosis in patients with follicular non-hodgkin's lymphoma, Role: Investigator, Genentech, Inc., (01/2014 - 01/2015) Status: Completed

Internal

  • Phase II trial of partial breast proton therapy for early stage breast cancer with low and intermediate risk factors, Role: Investigator, LLU Dept. of Radiation Medicine, (08/2024 - 07/2025) Status: Approved
  • Phase II trial of lumpectomy and partial breast proton therapy for early stage breast cancer, Role: Investigator, LLU Dept. of Radiation Medicine, (06/2024 - 06/2025) Status: Approved
  • ENCASe: Evaluation of needle core biopsy of axillary sentinel lymph node in breast cancer, Role: PI, LLU Dept. of Surgery, (10/2023 - 08/2024) Status: Completed
  • SHAVE 2: A multicenter randomized controlled trial of routine shave margins vs. standard partial mastectomy in breast cancer patients, Role: PI, LLU Dept. of Surgery, (07/2023 - 06/2024) Status: Completed
  • The Effect of the COVID-19 Pandemic on Breast Cancer Screening in Racial and Ethnic Minority Groups, Role: Investigator, LLU Dept. of Surgery, (05/2022) Status: Approved
  • Cancer care and surgical training in Africa: A needs assessment across the Pan-African Academy of Christian Surgeons (PAACS) and College of Surgeons of East, Central, and Southern Africa (COSECSA) general surgery residencies, Role: Investigator, LLU Dept. of Surgery, (10/2021 - 10/2023) Status: Approved
  • Investigator Initiated: Creation of registry for patients receiving neoadjuvant systemic therapy for Breast Cancer, Role: Investigator, LLU Dept. of Medicine, (01/2021) Status: Approved
  • Impact of COVID-19 pandemic on cancer screening and follow up, Role: PI, LLU Dept. of Surgery, (12/2020) Status: Approved
  • Impact of COVID-19 on screening mammogram use and follow up, Role: PI, LLU Dept. of Surgery, (11/2020) Status: Approved
  • Comparative Analysis of Diagnostic Rate and Cost of Percutaneous vs Excisional Lymph Node Biopsy, Role: PI, LLU Dept. of Surgery, (09/2020) Status: Approved
  • A retrospective study evaluating variants of uncertain significance (VUS) on breast cancer genetic cancer risk assessment and surgical decision making, Role: PI, LLU Dept. of Surgery, (07/2019 - 07/2020) Status: Completed
  • Outcomes of medical scribes in outpatient surgical settings, Role: PI, LLU Dept. of Surgery, (02/2019) Status: Approved
  • A retrospective study evaluating fibroepithelial breast lesions, Role: PI, LLU Dept. of Surgery, (06/2018 - 06/2019) Status: Completed
  • Outcomes of percutaneous breast and axillary biopsy, Role: PI, LLU Dept. of Surgery, (09/2016 - 09/2017) Status: Completed
  • Results of mastectomy: Single institution experience, Role: PI, LLU Dept. of Surgery, (09/2015) Status: Completed
  • Prevalance of overweight and obesity in a breast clinic population, Role: PI, LLU Dept. of Surgery, (01/2013 - 01/2014) Status: Completed
  • Evaluation of axillary ultrasound and biopsy for breast cancer patients, Role: PI, LLU Dept. of Surgery, (11/2010 - 11/2011) Status: Completed
  • Benefit and complication of breast reconstruction postmastectomy, Role: PI, LLU Dept. of Surgery, (07/2010) Status: Completed
  • Breast percutaneous needle biopsy, Role: PI, LLU Dept. of Surgery, (08/2009 - 08/2010) Status: Completed
  • Demographic disparities in BRCA testing, Role: PI, LLU Dept. of Surgery, (04/2008) Status: Completed
  • Colorectal cancer database review using the region 5 California cancer registry, Role: Investigator, LLU Dept. of Surgery, (01/2008) Status: Completed
  • Loma Linda University Medical Center's experience with the Gail Model: a retrospective study, Role: Investigator, LLU Dept. of Surgery, (10/2004 - 10/2005) Status: Completed
  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2024 - 09/2025) Status: Approved

Non-Profit Organization

  • NSABP B52: A randomized phase III trial evaluating pathologic complete response rates in patients with hormone receptor-positive, HER2-positive, large operable and locally advanced breast cancer treated with neoadjuvant therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) with or without estrogen deprivation, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (06/2024 - 06/2025) Status: Approved
  • NSABP B43: A phase III clinical trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-positive ductal carcinoma in situ resected by lumpectomy, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (12/2024 - 12/2025) Status: Approved
  • NSABP B51 / RTOG 1304: a randomized phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (09/2024 - 09/2025) Status: Approved
  • NSABP-B31 - A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by taxol (AC-T) to that of adriamycin and cyclophosphmide followed by taxol plus herceptin (AC-T+HC) in node-positive breast cancer patients who have tumors that overexpress HER2., Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (12/2019 - 12/2020) Status: Completed
  • NSABP - FB-7: A phase II randomized clinical trial evaluating neoadjuvant therapy regimens with weekly paclitaxel plus neratinib or trastuzumab or neratinib and trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-positive breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (07/2017 - 07/2018) Status: Completed
  • NSABP-B-38 - A Phase III, adjuvant trial comparing three chemotherapy regiments in women with node-positive breast cancer: docetaxel/doxorubicin/cyclophosphamide (TAC); dose-dense (DD) doxorubicin/cyclophosphamide followed by DD paclitaxel (DD AC P); DD AC followed by DD paclitaxel plus gemcitabine (DD AC PG), Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2015 - 11/2016) Status: Completed
  • NSABP-B-36 - A clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (08/2015 - 08/2016) Status: Completed
  • American College of Surgeons Oncology Group (ACOSOG) Protocol #Z0011 - A randomized trial of axillary node dissection in women with clinical T1 or T2 N0 M0 breast cancer who have a positive sentinel mode, Role: PI, American College of Surgeons Oncology Group, (06/2015 - 06/2016) Status: Completed
  • NSABP - B32 - A randomized, phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (09/2013 - 09/2014) Status: Completed
  • NSABP P-2 - Study of tamoxifen and raloxifene (STAR) for the prevention of breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (06/2012 - 06/2013) Status: Completed
  • NSABP-B30. A three-armed randomized trial to compare adjuvant adriamycin and cyclophosphamide followed by toxotere (AC-T); adriamycin and toxotere (AT); and adriamycin, taxotere, and cyclophosphamide (ATC) in breast cancer patients with positive axillary lymph nodes, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (03/2012 - 03/2013) Status: Completed
  • NSABP-B34 - A clinical trial comparing adjuvant clondronate therapy vs placebo in early-stage breast cancer patients receiving systemic chemotherapy and/or hormonal or no therapy, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (02/2012 - 02/2013) Status: Completed
  • NSABP B-27: A randomized trial comparing preoperative doxorubicin cyclophosphamide to preoperative AC followed by preoperative docetaxel and to preoperative AC followed by postoperative docetaxel in patients with operable carcinoma of the breast, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (03/2010 - 03/2011) Status: Completed
  • NSABP B-28. A Randomized Trial Evaluating the Worth of Paclitaxol (Taxol) Following Doxorubicin (Adriamycin)/Cyclophosphamide in Breast Cancer Patients with Positive Axillary Nodes, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2008 - 11/2009) Status: Completed
  • NSABP PROTOCOL C-09: A phase II clinical trial comparing oxaliplatin, capecitabine and hepatic arterial infusion of floxuridine to oxaliplatin and capecitabine in patients with resected or ablated liver metastases from colorectal cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2008 - 11/2009) Status: Completed
  • NSABP B-18. A 'Unified' Trial to Compare Short, Intensive Preoperative Systemic Adriamycin Cyclophosphamide Therapy with Similar Therapy Administered in Conventional Postoperative Fashion, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (11/2006 - 11/2007) Status: Completed
  • NSABP B-24. A clinical trial to evaluate the worth of Tamoxifen in conjunction with lumpectomy and breast irradiation for the treatment of noninvasive intraductal carcinoma of the breast, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (11/2006 - 11/2007) Status: Completed